Spero Therapeutics Inc (SPRO)
0.9375
+0.01
(+1.59%)
USD |
NASDAQ |
Dec 24, 16:00
Spero Therapeutics Cash from Operations (Quarterly): 12.76M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| CytomX Therapeutics Inc | -20.73M |
| Castle Biosciences Inc | 23.34M |
| Arbutus Biopharma Corp | -20.74M |
| PTC Therapeutics Inc | -76.99M |
| Equillium Inc | -7.657M |
Cash from Operations (Quarterly) Related Metrics
| Free Cash Flow | -17.54M |
| Free Cash Flow Per Share (Quarterly) | 0.2358 |
| Free Cash Flow to Equity (Quarterly) | 12.76M |
| Free Cash Flow to Firm (Quarterly) | 12.76M |
| Free Cash Flow Yield | -34.68% |